Short Interest Surge
Roivant Sciences Ltd. (ROIV) is experiencing a notable build in bearish sentiment. According to Ortex data as of November 7, 2026, short interest has reached 5.7% of the free float, marking a year-long high. This represents a roughly 10% increase over the past month, following a significant step-change in early October when short positions rose from approximately 36 million to current levels.
Borrowing Costs and Insider Activity
Despite the rising short interest, borrowing costs remain relatively low at 0.42%, down 15% over the last month, suggesting that the increase in short positions is not currently constrained by supply. The situation is further complicated by significant insider selling; Roivant President Eric Venker sold $21.1 million in stock across October and early November. While these were executed under 10b5-1 plans, the total 90-day net insider selling across the company has reached approximately $43.9 million, adding a layer of complexity to the stock's recent price performance.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.